{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:03:51Z","timestamp":1747181031327,"version":"3.40.5"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Allopurinol dose reduction proportional to creatinine clearance (CLcr) results in suboptimal urate lowering in patients with gout. Similarly, diuretic therapy reduces oxypurinol clearance but is unexpectedly associated with the need for higher allopurinol doses to achieve the serum urate target (&lt;0.36 mmol\/L). The authors aimed to clarify the relationship between oxypurinol exposure and urate-lowering response in patients with gout at different stages of chronic kidney disease and those taking diuretics to determine the implications for maintenance dose selection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Oxypurinol and urate data from 5 clinical studies were available. Model-derived steady-state oxypurinol areas under the concentration\u2013time curves (AUCss<jats:sub>0-tau<\/jats:sub>) were estimated using a Bayesian methodology. The observed response metrics included the percentage reduction in urate from baseline and achievement of the target urate level. Exposure\u2013response was explored graphically and using logistic regression. In addition, the influence of chronic kidney disease and diuretic use on the allopurinol dose and oxypurinol AUCss<jats:sub>0-tau<\/jats:sub> requirements to achieve the serum urate target were explored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Data from 258 patients with gout taking allopurinol representing 1288 paired steady-state oxypurinol and serum urate measurements were available. Higher oxypurinol exposure seems to be required for urate-lowering response normalization and achieve the serum urate target in individuals with reduced kidney function and those taking diuretics. However, allopurinol dose requirements were reduced by 2-fold at the extremes of kidney function and unchanged in those taking or not taking diuretics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A lower allopurinol maintenance dose was required in patients with reduced kidney function (CLcr &lt;30 mL\/min), but this was not proportional to CLcr. Diuretic therapy did not influence allopurinol dose requirements.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001265","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T15:01:04Z","timestamp":1730905264000},"page":"281-288","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Untangling the Exposure\u2013Response Relationship of Allopurinol in the Setting of Chronic Kidney Disease and Diuretic Use: Implications for Dosing"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8557-2766","authenticated-orcid":false,"given":"Hailemichael Z.","family":"Hishe","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Otago, Dunedin, New Zealand;"},{"name":"Pumas-AI Inc., DE ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia;"},{"name":"Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, Australia;"},{"name":"Musculoskeletal Health, University of Sydney, Sydney, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Otago, Christchurch, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Auckland, Auckland, New Zealand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony R.","family":"Merriman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand;"},{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-9252","authenticated-orcid":false,"given":"Daniel F. B.","family":"Wright","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia;"},{"name":"Department of Clinical Pharmacology & Toxicology, St Vincent's Hospital, Sydney, Australia;"},{"name":"St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-198611050-00001","article-title":"Clinical pharmacokinetics of allopurinol","volume":"11","author":"Murrell","year":"1986","journal-title":"Clin Pharmacokinet."},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/art.1780080429","article-title":"Role of the intestinal tract in the elimination of uric acid","volume":"8","author":"Sorensen","year":"1965","journal-title":"Arthritis Rheum."},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":"The pharmacokinetics of oxypurinol in people with gout","volume":"74","author":"Stocker","year":"2012","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","article-title":"The population pharmacokinetics of allopurinol and oxypurinol in patients with gout","volume":"69","author":"Wright","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cts.13460","article-title":"The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics","volume":"16","author":"Hishe","year":"2023","journal-title":"Clin Transl Sci."},{"key":"R7-20250314","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/bcp.16005","article-title":"The development and evaluation of dose\u2010prediction tools for allopurinol therapy (Easy\u2010Allo tools)","volume":"90","author":"Wright","year":"2024","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","article-title":"Predicting allopurinol response in patients with gout","volume":"81","author":"Wright","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/bcp.13307","article-title":"Individualising the dose of allopurinol in patients with gout","volume":"83","author":"Kannangara","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cpt.89","article-title":"Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response","volume":"97","author":"Wen","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dmpk.2018.09.002","article-title":"ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol","volume":"33","author":"Stamp","year":"2018","journal-title":"Drug Metab Pharmacokinet."},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dmpk.2017.11.002","article-title":"Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2","volume":"33","author":"Nakamura","year":"2018","journal-title":"Drug Metab Pharmacokinet."},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/cts.12992","article-title":"Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: influence of BCRP Q141K polymorphism and patient characteristics","volume":"14","author":"Vora","year":"2021","journal-title":"Clin Translational Sci."},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bcp.13516","article-title":"The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool","volume":"84","author":"Wright","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med."},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial."},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"R18-20250314","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum."},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","article-title":"Understanding the dose-response relationship of allopurinol: predicting the optimal dosage","volume":"76","author":"Graham","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"R21-20250314","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-018-1559-2","article-title":"Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort","volume":"20","author":"Ranieri","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"R22-20250314","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate-a complex drug interaction: implications for clinical practice","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology."},{"key":"R23-20250314","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.37925","article-title":"Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial","volume":"65","author":"Stamp","year":"2013","journal-title":"Arthritis Rheum."},{"key":"R24-20250314","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/bcp.15516","article-title":"An allopurinol adherence tool using plasma oxypurinol concentrations","volume":"89","author":"Smith-Diaz","year":"2023","journal-title":"Br J Clin Pharmacol."},{"key":"R25-20250314","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R26-20250314","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"R27-20250314","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.1988.tb03401.x","article-title":"Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion","volume":"26","author":"Day","year":"1988","journal-title":"Br J Clin Pharmacol."},{"key":"R28-20250314","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00315424","article-title":"Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy","volume":"39","author":"Peterson","year":"1990","journal-title":"Eur J Clin Pharmacol."},{"key":"R29-20250314","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxipurinol concentrations during allopurinol therapy","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol."},{"key":"R30-20250314","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","article-title":"Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease","volume":"14","author":"Panomvana","year":"2008","journal-title":"J Clin Rheumatol."},{"key":"R31-20250314","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/cts.12686","article-title":"Relationships between allopurinol dose, oxypurinol concentration and urate-lowering response\u2014in search of a minimum effective oxypurinol concentration","volume":"13","author":"Stamp","year":"2020","journal-title":"Clin Transl Sci."},{"key":"R32-20250314","first-page":"679","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Salem","year":"2017","journal-title":"Rheumatology"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:01:55Z","timestamp":1741964515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001265","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2024-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}